The Latest Cardiac and Vascular News
Trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint. However, the results validate the interaction between dalcetrapib treatment and AA genotype at variant rs1967309 in the ADCY9 gene. LONDON and MONTREAL, July 21, 2022 (GLOBE NEWSWIRE) — DalCor Pharmaceuticals announced the results of the […]
LONDON and MONTREAL, July 27, 2020 (GLOBE NEWSWIRE) — DalCor Pharmaceuticals today announced that the independent dal-GenE Data and Safety Monitoring Board (DSMB) recommends the dal-GenE pivotal outcomes trial should continue as planned with no modifications. This is an important milestone for DalCor and for cardiovascular patients with the ADCY9 […]
LONDON and MONTREAL, July 02, 2020 (GLOBE NEWSWIRE) — DalCor Pharmaceuticals today announced the appointment of Dr. David G. Kallend as Chief Scientific Officer effective July 1, 2020. Dr. Kallend joins DalCor from The Medicines Company where he held the position of Senior Vice President and Chief Medical Officer. He […]
LONDON and MONTREAL, Jan. 27, 2020 (GLOBE NEWSWIRE) — DalCor Pharmaceuticals today announced that following the results of the interim futility analysis of the dalcetrapib dal-GenE Phase 3 trial, DalCor will continue the dal-GenE trial as recommended by the independent Data and Safety Monitoring Board (DSMB). “We are pleased to […]
LONDON and MONTREAL, March 07, 2019 (GLOBE NEWSWIRE) — DalCor Pharmaceuticals today announced the appointment of Paul R. Fonteyne to Chairman of the Board effective February 27, 2019. “I am delighted to pass the baton to Paul Fonteyne who will assume the Chairmanship of DalCor,” said Robert McNeil, Ph.D., Chairman, […]
LONDON and MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) — DalCor today announced the completion of patient enrollment in the dal-GenE study, the first Phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease. The dal-GenE study is evaluating the efficacy of the CETP inhibitor dalcetrapib to reduce clinical cardiovascular […]
